Printer Friendly

A. L. LABORATORIES' SUBSIDIARIES CONFIRM RECEIPT OF FDA REQUEST

 FORT LEE, N.J., April 27 /PRNewswire/ -- A. L. Laboratories, Inc. (NYSE: BMD) today confirmed that certain of its U. S. Pharmaceutical subsidiaries are among the estimated 60 pharmaceutical companies, including the brand market leader, which have received a request from the Food and Drug Administration to discontinue the marketing of products containing iodinated glycerol. The company is continuing to monitor and review information related to FDA's request. Products which contain iodinated glycerol account for approximately 2 percent of the company's total annual revenues.
 Barre-National, the company's liquid pharmaceuticals subsidiary, has the broadest line of prescription cough and cold remedies in the U.S. generic pharmaceutical industry, and believes that other of its products could provide alternate therapies to products containing iodinated glycerol. Any potential earnings impact would depend upon the nature and timing of an actual product suspension, as well as the extent to which alternate therapies manufactured and marketed by the company are substituted for discontinued products.
 A. L. Laboratories, Inc. is a multinational manufacturer and marketer of specialized and value-added, branded pharmaceuticals and animal health micronutrients, with plant sites in Illinois, Maryland, New Jersey, New York, North Carolina, Washington State, Denmark and Indonesia.
 -0- 4/27/93
 /CONTACT: Iris Daniels of A.L. Laboratories, Inc., 201-947-7774, or David Walke or June Filingeri, both of Morgen-Walke Associates, 212-986-5900, for A.L. Laboratories/
 (BMD)


CO: A.L. Laboratories, Inc. ST: New Jersey IN: MCT SU:

TM -- NY129 -- 1695 04/27/93 18:50 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 27, 1993
Words:245
Previous Article:FDA PANEL SAYS THAT STUDIES SUPPORT SAFETY AND EFFICACY OF REACTINE(R), PFIZER'S ANTIHISTAMINE
Next Article:CARE: WESTIN'S 'TAKE CARE SUMMER' HELPS PUT A CHECK ON POVERTY AND HUNGER
Topics:


Related Articles
BARR RESPONDS TO FDA LAWSUIT
A.L. LABORATORIES ANNOUNCES AGREEMENT BETWEEN BARRE-NATIONAL AND THE FOOD AND DRUG ADMINISTRATION
A. L. LABORATORIES REPORTS THIRD QUARTER AND NINE MONTH RESULTS
A. L. LABORATORIES, INC. ANNOUNCES ACQUISITION
A. L. LABORATORIES ANNOUNCES FDA APPROVAL OF EPINEPHRINE MIST
A. L. LABORATORIES ANNOUNCES FDA APPROVAL OF CLOTRIMAZOLE VAGINAL CREAM
A. L. LABORATORIES ELABORATES ON SECOND QUARTER EARNINGS RELEASE
A. L. LABORATORIES REPORTS THIRD QUARTER AND NINE MONTH RESULTS
A. L. LABORATORIES ANNOUNCES RECEIPT OF THREE NEW PRODUCT APPROVALS FROM FDA
Barr Awaiting Approval for Generic Adderall(R) Tablets Begins Soliciting Customer Orders to Manage Anticipated Demand.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters